[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369137-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369137-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","impact-of-bone-modifying-agents-on-post-bone-metastasis-survival-across-cancer-types","Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types","","Bone metastasis is strongly linked to poor prognosis. Bone-modifying agents (BMA) are widely used to prevent or treat skeletal-related events (SRE), yet their effect on survival after bone metastasis is uncertain. In a retrospective analysis of 539 cancer patients, survival varied by cancer type, with longer post-bone metastasis survival in thyroid, breast, prostate, and kidney cancers and shorter survival in gastrointestinal, head and neck, and urinary tract cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/impact-of-bone-modifying-agents-on-post-bone-metastasis-survival-across-cancer-types/369137/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/impact-of-bone-modifying-agents-on-post-bone-metastasis-survival-across-cancer-types/369137.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-18","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address?","Question",{"text":63,"@type":64},"The study examines whether treatment with bone-modifying agents (BMA) improves survival after bone metastasis across different cancer types.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many patients were analyzed and what study design was used?",{"text":68,"@type":64},"A total of 539 cancer patients were retrospectively analyzed to identify independent factors associated with post-bone metastasis survival.",{"name":70,"@type":61,"acceptedAnswer":71},"Which cancer groups showed longer versus shorter median post-bone metastasis survival?",{"text":72,"@type":64},"Thyroid, breast, prostate, and kidney cancers had median survival longer than 24 months, while gastrointestinal, head and neck, and urinary tract cancers had significantly shorter median post-bone metastasis survival.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369137,1790508807,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article  \nImpact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types  \nHironari Tamiya 1,2,*, Kazumi Nishino 3, Yuji Kato 1, Reina Nakahashi-Kato 1, Yurika Kosuga-Tsujimoto 1, Shota Kinoshita 1, Rie Suzuki 2, Makiyo Watanabe 2, Toru Wakamatsu 2, Shigeki Kakunaga 2 and Satoshi Takenaka 2  \nReceived: 4 January 2025  \nAccepted: 13 January 2025  \nPublished: 15 January 2025  \nCitation: Tamiya, H.; Nishino, K.; Kato, Y.; Nakahashi-Kato, R.;  \nKosuga-Tsujimoto, Y.; Kinoshita, S.; Suzuki, R.; Watanabe, M.; Wakamatsu, T.; Kakunaga, S.; et al. Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types. Curr. Oncol. 2025, 32, 42 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)curroncol32010042  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Rehabilitation, Osaka International Cancer Institute, Osaka 541-8567, Japan; [yuuji.katou@oici.jp](yuuji.katou@oici.jp) (Y.K.); [nakahashir@opho.jp](nakahashir@opho.jp) (R.N.-K.); [kosugay@opho.jp](kosugay@opho.jp) (Y.K.-T.); [kinoshitash@opho.jp](kinoshitash@opho.jp) (S.K.)  \n2 Department of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan; [rie.suzuki@oici.jp](rie.suzuki@oici.jp) (R.S.); [makiyo.watanabe@oici.jp](makiyo.watanabe@oici.jp) (M.W.); [tooru.wakamatsu@oici.jp](tooru.wakamatsu@oici.jp) (T.W.); [shigeki.kakunaga@oici.jp](shigeki.kakunaga@oici.jp) (S.K.)  \n3 Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan; [kazumi.nishino@oici.jp](kazumi.nishino@oici.jp)  \n* [Correspondence: hironari.tamiya@oici.jp](Correspondence: hironari.tamiya@oici.jp)  \nAbstract: Background: Bone metastasis is associated with a poor prognosis. Bone-modifying agents (BMA) are commonly used for the prevention or treatment of skeletal-related events (SRE) in patients with bone metastasis; however, whether or not treatment with BMA improves survival remains unclear. In this study, we investigated whether BMA was involved in postbone metastasis survival. Methods: A total of 539 cancer patients were retrospectively analyzed to identify significant independent factors in post-bone metastasis survival. Results: Among the overall population, patients with the following cancers had a median survival longer than 24 months: thyroid, 97.2 months; breast, 51.5 months; prostate, 47.2 months; and kidney, 38.8 months. In contrast, median post-bone metastasis survival was significantly shorter in gastrointestinal (GI) (6.5 months), head and neck (6.3 months), and urinary tract (3.4 months) cancers. In non-small cell lung cancer (NSCLC), the log-rank test demonstrated that the epidermal growth factor receptor (EGFR) mutation was a significant factor for postbone metastasis survival: EGFR mutation (−) n = 67, median post-bone metastasis survival 11.5 months (95% CI: 6.0–15.2); EGFR mutation (+) n = 39, median post-bone metastasis survival 28.8 months (95% CI: 18.1–35.7) (p \u003C 0.05). Intriguingly, treatment with BMA was a significant positive prognostic factor: BMA (−) n = 203, median post-bone metastasis survival 7.8 months (95% CI: 5.8–12.5); BMA (+) n = 336, median post-bone metastasis survival 21.9 months (95% CI: 16.1–26.4) (p \u003C 0.001). Moreover, the Cox proportional hazards model showed that this was particularly evident in cancer types with poor prognosis such as GI cancer (hazard ratio [HR]: 0.62, 95% CI: 0.40–0.95; p \u003C 0.05) and NSCLC without the epidermal growth factor receptor (EGFR) mutation (HR: 0.56, 95% CI: 0.34–0.91; p \u003C 0.05). Conclusions: Treatment with BMA is recommended not only for the prevention and/or treatment of SRE, but also may have a positive impact o","cbCaimr06vfgiJ6C","https://ap.wps.com/l/cbCaimr06vfgiJ6C","pdf",4755808,13,"English","# Abstract\n## Introduction\n## Results\n## Conclusions","[{\"question\":\"What question does the study address?\",\"answer\":\"The study examines whether treatment with bone-modifying agents (BMA) improves survival after bone metastasis across different cancer types.\"},{\"question\":\"How many patients were analyzed and what study design was used?\",\"answer\":\"A total of 539 cancer patients were retrospectively analyzed to identify independent factors associated with post-bone metastasis survival.\"},{\"question\":\"Which cancer groups showed longer versus shorter median post-bone metastasis survival?\",\"answer\":\"Thyroid, breast, prostate, and kidney cancers had median survival longer than 24 months, while gastrointestinal, head and neck, and urinary tract cancers had significantly shorter median post-bone metastasis survival.\"}]","Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types | PDF",1790180931,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ab0a311ef33b619e7e0b910f2bc9fb9.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d67a4bffc59e0f0a7ee2742de4122749.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c150dd72b2ecede033656a9c3088633.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c6725d66200d225e3d277c66c9c147c.webp",980,1385]